|1.||Ahdieh, Harry: 2 articles (02/2007 - 01/2007)|
|2.||Rauck, Richard: 2 articles (02/2007 - 01/2007)|
|3.||Ma, Tina: 2 articles (02/2007 - 01/2007)|
|4.||Cheng, Duncan: 1 article (01/2015)|
|5.||Han, Bernadine: 1 article (01/2015)|
|6.||Odom, Anna E: 1 article (01/2015)|
|7.||Kotbi, Nabil: 1 article (01/2015)|
|8.||Sharma, Amit: 1 article (08/2014)|
|9.||Aggarwal, Aakash: 1 article (08/2014)|
|10.||Rane, Meghan: 1 article (08/2014)|
02/01/2007 - "Pain intensity increased significantly more for patients randomized to placebo than for patients who continued their stabilized dose of OPANA ER; the increase from baseline (at randomization) to final visit was 31.6 mm for placebo versus 8.7 mm with OPANA ER (P < .0001). "
02/01/2007 - "Patients continued slow titration, with 56% stabilized within 1 month to a dose of OPANA ER that reduced average pain to <40 mm on a visual analog scale with good tolerability. "
07/01/2007 - "Opana ER (oxymorphone extended release [ER]) is a new oral long-acting formulation indicated for the treatment of moderate to severe chronic pain. "
06/01/2010 - "Oxymorphone Extended-Release Tablets (Opana ER) For the Management of Chronic Pain: A Practical Review for Pharmacists."
01/11/2013 - "A case-control study was conducted, and investigators determined that the cases of TTP-like illness were associated with dissolving and injecting tablets of Opana ER (Endo Pharmaceuticals), a recently reformulated extended-release form of oxymorphone (an opioid pain reliever) intended for oral administration. "
|2.||Low Back Pain (Lumbago)
02/01/2007 - "Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study."
02/01/2007 - "Opioid-experienced (N = 250) patients with chronic, moderate to severe low back pain (LBP) were converted from their prestudy opioid(s) to an approximately equianalgesic dose of OPANA ER (oxymorphone extended release). "
01/01/2007 - "Determine the efficacy and tolerability of oxymorphone extended release (OPANA ER) in opioid-naive patients with moderate to severe chronic low back pain (CLBP). "
03/01/2011 - "A Comparison of Daily Average Consumption Of Oxycodone Controlled Release (OxyContin CR) And Oxymorphone Extended Release (Opana ER) In Patients With Low Back Pain."
02/01/2009 - "A secondary analysis was performed using data from a clinical trial involving 140 individuals with low back pain who were converted from prestudy opioids to an equianalgesic dose of an extended release (ER) formulation of oxymorphone (OPANA ER), which was then titrated to a stable dose [defined as visual analog scale <or=40 mm (0 to 100 mm) on 3 of 5 consecutive days and requiring <or=2 doses rescue medication]. "
|3.||Thrombotic Thrombocytopenic Purpura
01/01/2015 - "Opana(®) ER induced thrombotic thrombocytopenic purpura."
08/01/2014 - "Resurgence of intravenous Opana as a cause of secondary thrombotic thrombocytopenic purpura."
01/01/2014 - "Recent report of Opana ER intravenous abuse was published from Tennessee county and has now been increasingly recognised as one of the causes of thrombocytopenia which mimicks clinically as thrombotic thrombocytopenic purpura. "
01/01/2014 - "Opana ER abuse and thrombotic thrombocytopenic purpura (TTP)-like illness: a rising risk factor in illicit drug users."
01/11/2013 - "Thrombotic thrombocytopenic purpura (TTP)-like illness associated with intravenous Opana ER abuse--Tennessee, 2012."
07/01/2014 - "We report a similar case series of 15 patients with 18 episodes of thrombotic microangiopathy associated with recent IV abuse of oral Opana ER. "
01/01/2014 - "She was found to have clinical evidence of profound thrombotic microangiopathy which resulted due to the intravenous use of Opana ER. "
07/01/2014 - "Thus, it appears that plasma exchange with associated costs and risks can be safely omitted in patients with thrombotic microangiopathy resulting from IV abuse of oral Opana ER."
07/01/2014 - "Successful treatment of intravenously abused oral Opana ER-induced thrombotic microangiopathy without plasma exchange."
|3.||thymidine 5'-triphosphate (TTP)
|5.||Opioid Analgesics (Opioids)